[go: up one dir, main page]

CL2014002269A1 - Método para predecir sensibilidad de crecimiento celular tumoral a un inhibidor de wnt por medio de determinación de estado de mutación de región cromosómica rnf43; kit; composición farmacéutica que comprende inhibidor de wnt útil para tratar cáncer de pancreas. - Google Patents

Método para predecir sensibilidad de crecimiento celular tumoral a un inhibidor de wnt por medio de determinación de estado de mutación de región cromosómica rnf43; kit; composición farmacéutica que comprende inhibidor de wnt útil para tratar cáncer de pancreas.

Info

Publication number
CL2014002269A1
CL2014002269A1 CL2014002269A CL2014002269A CL2014002269A1 CL 2014002269 A1 CL2014002269 A1 CL 2014002269A1 CL 2014002269 A CL2014002269 A CL 2014002269A CL 2014002269 A CL2014002269 A CL 2014002269A CL 2014002269 A1 CL2014002269 A1 CL 2014002269A1
Authority
CL
Chile
Prior art keywords
wnt inhibitor
kit
pharmaceutical composition
cell growth
tumor cell
Prior art date
Application number
CL2014002269A
Other languages
English (en)
Inventor
Feng Cong
Huaixiang Hao
Hsin-I Hsieh
Xiaomo Jiang
Jun Liu
Nicholas Ng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47790546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002269(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2014002269A1 publication Critical patent/CL2014002269A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014002269A 2012-02-28 2014-08-27 Método para predecir sensibilidad de crecimiento celular tumoral a un inhibidor de wnt por medio de determinación de estado de mutación de región cromosómica rnf43; kit; composición farmacéutica que comprende inhibidor de wnt útil para tratar cáncer de pancreas. CL2014002269A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261604290P 2012-02-28 2012-02-28

Publications (1)

Publication Number Publication Date
CL2014002269A1 true CL2014002269A1 (es) 2014-12-19

Family

ID=47790546

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002269A CL2014002269A1 (es) 2012-02-28 2014-08-27 Método para predecir sensibilidad de crecimiento celular tumoral a un inhibidor de wnt por medio de determinación de estado de mutación de región cromosómica rnf43; kit; composición farmacéutica que comprende inhibidor de wnt útil para tratar cáncer de pancreas.

Country Status (19)

Country Link
US (3) US20150125857A1 (es)
EP (2) EP2820151B1 (es)
JP (2) JP6397335B2 (es)
KR (1) KR20140132712A (es)
CN (1) CN104302782A (es)
AU (1) AU2013226323B2 (es)
BR (1) BR112014020233A2 (es)
CA (1) CA2864306A1 (es)
CL (1) CL2014002269A1 (es)
ES (2) ES2968742T3 (es)
IL (1) IL233920A0 (es)
MX (1) MX2014010265A (es)
NZ (1) NZ627864A (es)
PH (1) PH12014501930A1 (es)
RU (2) RU2636000C2 (es)
SG (1) SG11201404492VA (es)
TN (1) TN2014000337A1 (es)
WO (1) WO2013130364A1 (es)
ZA (1) ZA201405553B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260519B2 (en) 2011-06-17 2016-02-16 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
ES2769786T3 (es) 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
ES2968742T3 (es) 2012-02-28 2024-05-13 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
CN105142641A (zh) 2013-03-12 2015-12-09 广州源生医药科技有限公司 用于治疗癌症的化合物
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
MX2016013857A (es) * 2014-04-21 2017-07-14 Abbvie Stemcentrx Llc Anticuerpos anti-rnf43 novedosos y metodos de uso.
MX373651B (es) * 2014-10-08 2020-03-31 Redx Pharma Plc Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt.
US20160312207A1 (en) * 2015-04-21 2016-10-27 The Board Of Trustees Of The Leland Stanford Junior University R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling
EP3302479A4 (en) * 2015-05-26 2019-01-09 Curegenix Corporation TUMOR BIOMARKERS AND USE THEREOF
CA3049661A1 (en) 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (rspo) surrogate molecules
CN110234662A (zh) * 2017-01-26 2019-09-13 瑟罗泽恩公司 组织特异性wnt信号增强分子和其用途
WO2019245460A1 (en) * 2018-06-21 2019-12-26 National University Of Singapore Stratifying cancer patients harbouring oncogenic mutations in the e3 ubiquitin ligase rnf43
EP3820499A4 (en) 2018-07-09 2022-07-13 Surrozen Operating, Inc. TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
WO2020257758A1 (en) * 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
CN113564249B (zh) * 2020-04-28 2023-06-16 中国科学院分子细胞科学卓越创新中心 CXorf67在判断肿瘤对DNA损伤药物的敏感性中的应用
TW202233656A (zh) 2020-11-16 2022-09-01 美商蘇羅森營運公司 肝特異性wnt訊號增強分子及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536439A (ja) 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法
CN100532549C (zh) * 2002-06-06 2009-08-26 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
SI1513934T1 (sl) * 2002-06-06 2011-06-30 Oncotherapy Science Inc Geni in polipeptidi, povezani s humanimi raki kolona
CA2501235A1 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
US7718364B2 (en) 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
AU2005271763A1 (en) * 2004-07-09 2006-02-16 The Regents Of The University Of California Methods for treating cancer using agents that inhibit Wnt16 signaling
NZ555216A (en) * 2004-11-10 2010-05-28 Hubrecht Lab Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
DE602006016085D1 (de) 2005-03-16 2010-09-23 Genentech Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2011004379A1 (en) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
EP2549399A1 (en) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
ES2769786T3 (es) 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
ES2968742T3 (es) 2012-02-28 2024-05-13 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
AR106949A1 (es) 2015-12-04 2018-03-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales

Also Published As

Publication number Publication date
WO2013130364A1 (en) 2013-09-06
JP2018172408A (ja) 2018-11-08
SG11201404492VA (en) 2014-10-30
RU2636000C2 (ru) 2017-11-17
US20190203301A1 (en) 2019-07-04
US20150125857A1 (en) 2015-05-07
ZA201405553B (en) 2015-12-23
IL233920A0 (en) 2014-09-30
EP3693476A1 (en) 2020-08-12
JP6397335B2 (ja) 2018-09-26
EP3693476B1 (en) 2023-10-18
ES2797533T3 (es) 2020-12-02
TN2014000337A1 (en) 2015-12-21
NZ627864A (en) 2015-12-24
MX2014010265A (es) 2015-06-23
EP2820151A1 (en) 2015-01-07
PH12014501930A1 (en) 2014-11-24
AU2013226323A1 (en) 2014-09-11
BR112014020233A2 (pt) 2017-07-04
JP2015511484A (ja) 2015-04-20
RU2017120287A (ru) 2018-11-15
ES2968742T3 (es) 2024-05-13
AU2013226323B2 (en) 2016-07-14
RU2014139044A (ru) 2016-04-20
EP2820151B1 (en) 2020-03-25
US20170306409A1 (en) 2017-10-26
HK1199744A1 (en) 2015-07-17
KR20140132712A (ko) 2014-11-18
CN104302782A (zh) 2015-01-21
CA2864306A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
CL2014002269A1 (es) Método para predecir sensibilidad de crecimiento celular tumoral a un inhibidor de wnt por medio de determinación de estado de mutación de región cromosómica rnf43; kit; composición farmacéutica que comprende inhibidor de wnt útil para tratar cáncer de pancreas.
BR112014002616A2 (pt) método para detectar cãncer pancreático e reagente ou kit para detectar câncer pancreático
BR112013025006A2 (pt) composições e métodos para inibição de expressão do gene tmprss6
SI2753334T1 (sl) Fap-aktivirani proteasomski inhibitorji za zdravljenje solidnih tumorjev
HUE057264T2 (hu) Eljárás új IDH1 inhibitorok elõállítására
GB2487632B (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
JO3450B1 (ar) أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
IL231813A0 (en) Use of preparations containing ATR inhibitors for the treatment of pancreatic cancer and non-small cell lung cancer
CO6761389A2 (es) Inhibidores de nampt y rock
DK3147373T3 (da) Fremgangsmåde til anvendelse af genekspression til at bestemme prognosen for prostatacancer
EP2776830A4 (en) METHOD FOR PREDICTING BREAST CANCER PROGNOSIS
PT3581654T (pt) Métodos e composições para a inibição específica de glicolato oxidase (hao1) por rna de cadeia dupla
WO2014055543A3 (en) Biomarkers and methods to predict response to inhibitors and uses thereof
EP2831281A4 (en) MOLECULAR MARKERS FOR THE PROGNOSTIC PREDICTION OF PROSTATE CANCER, METHOD AND KIT THEREFOR
BR112014000443A2 (pt) métodos e ácidos nucléicos para determinação do prognóstico de um indivíduo com câncer
EP2911691A4 (en) PROCESS FOR TREATING NEUROENDOCRIN TUMORS WITH WNT PAD BINDERS
MX2013014622A (es) Enfermedad tromboembolica.
CL2015000192A1 (es) Método de seleccion de un sujeto que padece un tumor maligno para tratamiento con inhibidor de jak/stat que comprende determinar nivel de expresión de biomarcadores.
GT201300078A (es) Proceso para la preparacion de inhibidores de pan-cdk de la formula ( i ), e intermediarios de la preparacion
UY34355A (es) Composición ecológica para curtido
EP2908136A4 (en) METHOD AND KIT FOR THE DISTINCTION BETWEEN A PROSTATE CARCINOMA AND BENIGNER PROSTATE HYPERPLASIA
BR112014005505A2 (pt) substrato de polinucleotídeo isolado para uma enzima de ácido nucleico catalítica, método para detectar a presença de pelo menos um alvo, uso do substrato de polinucleotídeo isolado e kit
BR112013029484A2 (pt) método para o tratamento de tumores sólidos avançados